What is NSCLC Phase I MEDI4736 Tremelimumab Study?

Category: Others

false

MEDI4736 Tremelimumab is a phase 1 trial assessing the safety and tolerability of MEDI4736 with tremelimumab in patients with non-small cell lung cancer (NSCLC).

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 1
Moderate 0
Mild 0
None 0

Commonly reported side effects and conditions associated with NSCLC Phase I MEDI4736 Tremelimumab Study

Side effect Patients
Ulcerative colitis 1

Why patients stopped taking NSCLC Phase I MEDI4736 Tremelimumab Study

Multiple reasons could be selected

Reason Patients
Side effects too severe 1
See 1 patient who's stopped using NSCLC Phase I MEDI4736 Tremelimumab Study

Duration

Stopped using NSCLC Phase I MEDI4736 Tremelimumab Study

Duration Patients
1 - 6 months 1
Adherence
Adherence Evaluations
Always 0
Usually 0
Sometimes 0
Never taken as prescribed 1
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 1
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 1
Not specified 0
Last updated:
There are no evaluations for NSCLC Phase I MEDI4736 Tremelimumab Study.